MX2016010011A - Metodos para tratar y prevenir trastornos renales y trastornos del higado graso. - Google Patents
Metodos para tratar y prevenir trastornos renales y trastornos del higado graso.Info
- Publication number
- MX2016010011A MX2016010011A MX2016010011A MX2016010011A MX2016010011A MX 2016010011 A MX2016010011 A MX 2016010011A MX 2016010011 A MX2016010011 A MX 2016010011A MX 2016010011 A MX2016010011 A MX 2016010011A MX 2016010011 A MX2016010011 A MX 2016010011A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- methods
- fatty liver
- prevention
- treatment
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000004930 Fatty Liver Diseases 0.000 title abstract 2
- 206010019708 Hepatic steatosis Diseases 0.000 title abstract 2
- 208000010706 fatty liver disease Diseases 0.000 title abstract 2
- 231100000240 steatosis hepatitis Toxicity 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229960001713 canagliflozin Drugs 0.000 abstract 2
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 abstract 2
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 238000011262 co‐therapy Methods 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934003P | 2014-01-31 | 2014-01-31 | |
| US201461948882P | 2014-03-06 | 2014-03-06 | |
| PCT/US2015/013644 WO2015116880A1 (en) | 2014-01-31 | 2015-01-30 | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016010011A true MX2016010011A (es) | 2016-10-07 |
Family
ID=52544570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010011A MX2016010011A (es) | 2014-01-31 | 2015-01-30 | Metodos para tratar y prevenir trastornos renales y trastornos del higado graso. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20160339047A1 (OSRAM) |
| EP (1) | EP3099328A1 (OSRAM) |
| JP (2) | JP2017504649A (OSRAM) |
| KR (1) | KR20160107344A (OSRAM) |
| CN (3) | CN113082021A (OSRAM) |
| AU (2) | AU2015210898A1 (OSRAM) |
| CA (1) | CA2938406A1 (OSRAM) |
| EA (1) | EA201691555A1 (OSRAM) |
| IL (1) | IL246779A0 (OSRAM) |
| MX (1) | MX2016010011A (OSRAM) |
| WO (1) | WO2015116880A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2998509A1 (en) * | 2015-09-16 | 2017-03-23 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| PL3370776T3 (pl) * | 2015-11-06 | 2024-08-05 | Gelteq Limited | Sposób i produkt do badania odpowiedzi na doustne obciążenie glukozą |
| GB201614455D0 (en) * | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| TWI835735B (zh) * | 2017-06-12 | 2024-03-21 | 比利時商健生藥品公司 | 減少或預防第ii型糖尿病患者中心血管事件之方法 |
| CN109806397A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途 |
| MA51203A (fr) | 2017-11-30 | 2020-10-07 | Idorsia Pharmaceuticals Ltd | Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline |
| TW202103709A (zh) * | 2019-03-26 | 2021-02-01 | 比利時商健生藥品公司 | 用於治療患有慢性腎臟病之對象的方法 |
| CN110051851A (zh) * | 2019-05-31 | 2019-07-26 | 江苏苏中药业集团股份有限公司 | 一种钠-葡萄糖共转运蛋白-2抑制剂与黄蜀葵花提取物的组合 |
| CN116490178A (zh) * | 2020-08-17 | 2023-07-25 | 北京睿创康泰医药研究院有限公司 | Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途 |
| CA3197706A1 (en) * | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| WO2022104621A1 (zh) * | 2020-11-19 | 2022-05-27 | 北京睿创康泰医药研究院有限公司 | 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途 |
| JP2024094532A (ja) | 2022-12-28 | 2024-07-10 | キヤノン株式会社 | 撮像設定装置および撮像装置 |
| KR20240126452A (ko) * | 2023-02-10 | 2024-08-21 | 가천대학교 산학협력단 | 칸데사르탄 또는 아질사르탄을 포함하는 조성물의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL322529A1 (en) * | 1995-04-07 | 1998-02-02 | Ciba Geigy Ag | Complex compositions containing benazeoprile or benazeprilate and valsartan |
| KR100942622B1 (ko) | 2003-08-01 | 2010-02-17 | 미쓰비시 타나베 파마 코퍼레이션 | 나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물 |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| WO2008113095A1 (en) * | 2007-03-20 | 2008-09-25 | Fibrotech Therapeutics Pty Ltd | Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb) |
| UY32030A (es) * | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| EP2389178A4 (en) * | 2008-12-01 | 2012-06-06 | Invasc Therapeutic Inc | COMPOSITIONS CONTAINING INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND LIPOIC ACID COMPOUNDS, AND THEIR USE FOR THE TREATMENT OF RENIN-ANGIOTENSIN-ALDOSTERONE ASSOCIATED DISORDERS |
| ES2836508T3 (es) * | 2009-03-26 | 2021-06-25 | Ajay Gupta | Composiciones y métodos para el tratamiento de la enfermedad renal |
| JP2013523681A (ja) * | 2010-03-30 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用 |
| JP5889321B2 (ja) * | 2010-11-04 | 2016-03-22 | アルビレオ アクチエボラグ | 肝疾患の処置用のｉｂａｔ阻害剤 |
| AU2011327903A1 (en) * | 2010-11-11 | 2013-05-02 | Redx Pharma Plc | Drug derivatives |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
-
2015
- 2015-01-30 WO PCT/US2015/013644 patent/WO2015116880A1/en not_active Ceased
- 2015-01-30 EP EP15705743.1A patent/EP3099328A1/en not_active Withdrawn
- 2015-01-30 US US15/112,786 patent/US20160339047A1/en not_active Abandoned
- 2015-01-30 JP JP2016549388A patent/JP2017504649A/ja not_active Withdrawn
- 2015-01-30 CN CN202110463410.XA patent/CN113082021A/zh active Pending
- 2015-01-30 CN CN201580006608.8A patent/CN105939728A/zh active Pending
- 2015-01-30 CN CN202110463431.1A patent/CN113144204A/zh active Pending
- 2015-01-30 AU AU2015210898A patent/AU2015210898A1/en not_active Abandoned
- 2015-01-30 MX MX2016010011A patent/MX2016010011A/es unknown
- 2015-01-30 EA EA201691555A patent/EA201691555A1/ru unknown
- 2015-01-30 CA CA2938406A patent/CA2938406A1/en not_active Abandoned
- 2015-01-30 KR KR1020167023439A patent/KR20160107344A/ko not_active Ceased
-
2016
- 2016-07-14 IL IL246779A patent/IL246779A0/en unknown
-
2018
- 2018-07-20 US US16/040,580 patent/US20180344756A1/en not_active Abandoned
-
2020
- 2020-01-16 JP JP2020005106A patent/JP2020090511A/ja active Pending
- 2020-12-02 AU AU2020281039A patent/AU2020281039A1/en not_active Abandoned
-
2021
- 2021-01-05 US US17/141,248 patent/US20210121492A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017504649A (ja) | 2017-02-09 |
| CA2938406A1 (en) | 2015-08-06 |
| CN105939728A (zh) | 2016-09-14 |
| CN113082021A (zh) | 2021-07-09 |
| AU2020281039A1 (en) | 2021-01-07 |
| CN113144204A (zh) | 2021-07-23 |
| EP3099328A1 (en) | 2016-12-07 |
| US20180344756A1 (en) | 2018-12-06 |
| IL246779A0 (en) | 2016-08-31 |
| WO2015116880A1 (en) | 2015-08-06 |
| US20160339047A1 (en) | 2016-11-24 |
| EA201691555A1 (ru) | 2017-01-30 |
| KR20160107344A (ko) | 2016-09-13 |
| AU2015210898A1 (en) | 2016-07-28 |
| US20210121492A1 (en) | 2021-04-29 |
| JP2020090511A (ja) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010011A (es) | Metodos para tratar y prevenir trastornos renales y trastornos del higado graso. | |
| IL273824A (en) | Methods of using ehmt2 inhibitors in the treatment or prevention of blood disorders | |
| MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
| ZA202007007B (en) | Mcl-1 inhibitors | |
| ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
| PH12019501010A1 (en) | Arginase inhibitor combination therapies | |
| MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| MX2018004947A (es) | Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados. | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| EA201990951A1 (ru) | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
| ZA201700196B (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| MX2017006464A (es) | Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton. | |
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| PH12018550186A1 (en) | Pharmaceutical combinations for treating cancer | |
| EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
| EA201791933A1 (ru) | Ингибирование активности olig2 | |
| PH12016502322B1 (en) | Compounds and methods for preventing or treating malaria | |
| MY205171A (en) | Methods of treatment of hypertriglyceridemia | |
| NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
| MX2020001759A (es) | Inhibidores de histona acetiltransferasa de la familia myst. | |
| MX2017003020A (es) | Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa. |